FURIN: The Cardiovascular Protein Factory
Every bioactive peptide in your body starts life as an inactive precursor — a
pro-protein that must be cleaved into its functional form. FURIN (also called
PCSK311 PCSK3
proprotein convertase subtilisin/kexin type 3)
is one of the most important enzymes responsible for these cuts. Its substrates
include pro-BNP and pro-ANP22 pro-BNP and pro-ANP
heart-secreted hormones that lower blood pressure
and reduce fluid retention,
pro-renin33 pro-renin
the inactive form of renin, the first enzyme in the blood-pressure-
raising renin-angiotensin-aldosterone cascade,
pro-endothelin-1, and pro-TGF-β. Essentially, FURIN sits at the top of multiple
cardiovascular control systems simultaneously. The variant rs17514846, located
in an intron of the FURIN gene on chromosome 15q26.1, alters how much of this
enzyme is produced — with consequences for both coronary artery disease risk and
blood pressure regulation.
The Mechanism
The rs17514846 variant operates through allele-specific epigenetic regulation44 allele-specific epigenetic regulation
the same DNA sequence making different amounts of protein depending on chemical
marks attached to it. The C allele
contains a CpG dinucleotide — a sequence prone to methylation — directly at the
variant position. When methylated, this CpG recruits the transcription repressor
MeCP255 MeCP2
methyl-CpG-binding protein 2, a protein that binds methylated DNA and
turns off nearby genes, which
silences FURIN expression. The A allele, by contrast, destroys the CpG motif
entirely — there is nothing to methylate, nothing to recruit MeCP2, and FURIN
expression remains higher. Researchers confirmed this by treating C/C cells with
a DNA methylation inhibitor, which increased FURIN expression to A/A levels.
In macrophages66 macrophages
immune cells that accumulate in atherosclerotic plaques and
are central to plaque development,
higher FURIN from the A allele drives three pro-atherogenic behaviors: increased
migration into arterial walls, faster proliferation, and reduced programmed cell
death. The same phenomenon occurs in vascular endothelial cells77 vascular endothelial cells
the cells
lining artery walls that control what enters and exits the vessel wall:
A-allele carriers show higher FURIN expression, elevated endothelin-1 (a potent
vasoconstrictor), activated NF-κB signaling, more VCAM-1 and MCP-1, and
greater monocyte adhesion and transendothelial migration — all hallmarks of
early atherosclerosis.
The Evidence
The association between the chromosome 15q26.1 locus and coronary artery disease
was first robustly established in GWAS meta-analyses through the
CARDIoGRAMplusC4D consortium88 CARDIoGRAMplusC4D consortium
a mega-consortium pooling CAD genetic data
from hundreds of thousands of individuals.
The A allele confers approximately 1.04–1.07-fold increased CAD risk99 1.04–1.07-fold increased CAD risk
a modest individual OR but important population-level effect given the high
allele frequency. In the Bruneck
Study, A-allele carriers showed
higher circulating MCP-1 and greater carotid intima-media thickness1010 higher circulating MCP-1 and greater carotid intima-media thickness
two established intermediate biomarkers on the path to clinical heart disease.
The blood pressure dimension involves a related but partially independent
mechanism. The ICBP/Global BPgen consortium GWAS in 200,000 Europeans1111 The ICBP/Global BPgen consortium GWAS in 200,000 Europeans
Ehret et al., Nature 2011
identified the FURIN-FES locus among those with genome-wide significant
associations with systolic and diastolic blood pressure. The biology is
consistent: when FURIN processes pro-BNP and pro-ANP into their active
natriuretic forms, blood pressure falls. When FURIN processes pro-renin
receptor (PRR) to regulate RAAS activity, blood pressure is modulated from
the other direction. Higher FURIN from the A allele therefore activates
intersecting vasodilatory and vasoconstrictive pathways simultaneously —
net effect depends on tissue context and disease stage.
A Japanese cohort study found A-allele carriers had significantly lower triglycerides and higher HDL, suggesting metabolic syndrome protection in that population — an apparently paradoxical protective metabolic effect coexisting with elevated CAD risk through the vascular biology pathway.
Practical Actions
For A-allele carriers, the elevated atherosclerosis biology argues for aggressive management of all modifiable cardiovascular risk factors — not because of generic health advice, but because the genetic burden this variant adds is magnified by other risk factors. Specifically: measuring carotid intima-media thickness (CIMT) provides a direct readout of the subclinical atherosclerosis this variant promotes, and early detection allows intervention before clinical events occur. The inflammation axis (elevated MCP-1, VCAM-1, endothelin-1) makes high-sensitivity CRP a particularly informative biomarker for this genotype.
Carriers of two A alleles (AA genotype, approximately 23% globally) bear the greatest FURIN elevation and the highest cumulative risk. For them, cardiac screening conversations with a physician — including coronary calcium scoring when age-appropriate — are warranted earlier than population guidelines suggest.
Interactions
The rs17514846 locus includes several SNPs in high linkage disequilibrium —
rs6224, rs11372849, and rs8039305 — that may contribute additional regulatory
effects. The cis-eQTL variant rs47021212 rs4702
a FURIN 3'-UTR variant associated with
both blood pressure and schizophrenia risk
appears in partial LD with rs17514846 and affects FURIN expression through
a distinct molecular mechanism, suggesting additive effects in individuals
carrying both. There are no well-characterized interactions with other SNPs
already in this database, but FURIN's broad substrate range means variants
in RAAS genes (AGT rs699, AGTR1 rs5186) that affect the same blood pressure
pathways could compound cardiovascular risk in a clinically meaningful way.